Preclinical and clinical development of palbociclib and future perspectives

• E. Martínez de Dueñas ^[4] ; J. Gavila-Gregori ^[1] ; S. Olmos-Antón ^[4] ; A. Santaballa-Bertrán ^[2] ; A. Lluch-Hernández ^[5] ; E. J. Espinal-Domínguez ^[6] ; M. Rivero-Silva ^[6] ; A. Llombart-Cussac ^[3]
  1. [1] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  2. [2] Hospital Universitario La Fe

     Hospital Universitario La Fe

     Valencia, España

     
  3. [3] Hospital Universitario Arnau de Vilanova

     Hospital Universitario Arnau de Vilanova

     Lérida, España

     
  4. [4] Hospital Provincial de Castellón, España
  5. [5] Hospital Clínico Universiatrio de Valencia, España
  6. [6] Pfizer Inc, Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 9 (September 2018), 2018, págs. 1136-1144
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy. This review describes the mechanism of action, preclinical experiences and clinical data of palbociclib, with a special focus on integrating this data with the positioning of palbociclib in the current clinical guidelines for advanced HR-positive/HER2-negative breast cancer. Aspects of the ongoing major studies are also presented, as well as future prospects in the development of palbociclib.